BR112018008900A8 - composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas - Google Patents
composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmasInfo
- Publication number
- BR112018008900A8 BR112018008900A8 BR112018008900A BR112018008900A BR112018008900A8 BR 112018008900 A8 BR112018008900 A8 BR 112018008900A8 BR 112018008900 A BR112018008900 A BR 112018008900A BR 112018008900 A BR112018008900 A BR 112018008900A BR 112018008900 A8 BR112018008900 A8 BR 112018008900A8
- Authority
- BR
- Brazil
- Prior art keywords
- uveitis
- compositions
- methods
- macular edema
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250269P | 2015-11-03 | 2015-11-03 | |
| EP16306166 | 2016-09-14 | ||
| US201662408391P | 2016-10-14 | 2016-10-14 | |
| PCT/US2016/060344 WO2017079443A1 (en) | 2015-11-03 | 2016-11-03 | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018008900A2 BR112018008900A2 (pt) | 2018-11-06 |
| BR112018008900A8 true BR112018008900A8 (pt) | 2019-02-26 |
Family
ID=57018106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018008900A BR112018008900A8 (pt) | 2015-11-03 | 2016-11-03 | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10968278B2 (https=) |
| EP (1) | EP3371224B1 (https=) |
| JP (4) | JP7272794B2 (https=) |
| KR (2) | KR102930886B1 (https=) |
| CN (1) | CN108473583A (https=) |
| AU (2) | AU2016348418B8 (https=) |
| BR (1) | BR112018008900A8 (https=) |
| CA (1) | CA3003874A1 (https=) |
| IL (1) | IL319993A (https=) |
| MX (2) | MX2018005589A (https=) |
| SG (1) | SG11201803654TA (https=) |
| TW (3) | TWI786636B (https=) |
| WO (1) | WO2017079443A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| WO2017079443A1 (en) | 2015-11-03 | 2017-05-11 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
| SG11202101674QA (en) | 2018-08-29 | 2021-03-30 | Regeneron Pharma | Methods and compositions for treating subjects having rheumatoid arthritis |
| MA54861A (fr) | 2019-01-31 | 2021-12-08 | Regeneron Pharma | Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile |
| SG11202111742QA (en) | 2019-04-24 | 2021-11-29 | Sanofi Biotechnology | Methods of diagnosis and treatment of rheumatoid arthritis |
| CA3142710A1 (en) | 2019-06-04 | 2020-12-10 | Sanofi Biotechnology | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
| CN114375205A (zh) | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| CA3195967A1 (en) * | 2020-10-28 | 2022-05-05 | Xu Wang | Vectorized anti-tnf-? antibodies for ocular indications |
| IL318765A (en) * | 2022-10-24 | 2025-04-01 | Hoffmann La Roche | Predicting response to IL-6 antagonists |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| ES2384222T3 (es) | 1994-10-07 | 2012-07-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo |
| UA66757C2 (en) | 1996-02-26 | 2004-06-15 | Advanced Res & Tech Inst | Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| CN1989439B (zh) | 2004-05-06 | 2010-12-29 | 美国政府健康及人类服务部 | 治疗葡萄膜炎的方法以及组合物 |
| US8080248B2 (en) * | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| MX2010012031A (es) * | 2008-05-13 | 2011-01-20 | Novimmune Sa | Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos. |
| BR112012028557A2 (pt) | 2010-05-07 | 2019-09-24 | Xoma Technology Ltd. | uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo. |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| CN104903349B (zh) * | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| MX377190B (es) | 2013-11-22 | 2025-03-07 | Sanofi Biotechnology | Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| WO2017079443A1 (en) | 2015-11-03 | 2017-05-11 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
-
2016
- 2016-11-03 WO PCT/US2016/060344 patent/WO2017079443A1/en not_active Ceased
- 2016-11-03 AU AU2016348418A patent/AU2016348418B8/en active Active
- 2016-11-03 CA CA3003874A patent/CA3003874A1/en active Pending
- 2016-11-03 US US15/342,833 patent/US10968278B2/en active Active
- 2016-11-03 KR KR1020187015533A patent/KR102930886B1/ko active Active
- 2016-11-03 IL IL319993A patent/IL319993A/en unknown
- 2016-11-03 BR BR112018008900A patent/BR112018008900A8/pt not_active Application Discontinuation
- 2016-11-03 TW TW110117779A patent/TWI786636B/zh active
- 2016-11-03 SG SG11201803654TA patent/SG11201803654TA/en unknown
- 2016-11-03 TW TW105135684A patent/TWI729022B/zh active
- 2016-11-03 EP EP16810513.8A patent/EP3371224B1/en active Active
- 2016-11-03 CN CN201680077216.5A patent/CN108473583A/zh active Pending
- 2016-11-03 MX MX2018005589A patent/MX2018005589A/es unknown
- 2016-11-03 KR KR1020267005251A patent/KR20260036589A/ko active Pending
- 2016-11-03 TW TW111143328A patent/TW202339795A/zh unknown
- 2016-11-03 JP JP2018543040A patent/JP7272794B2/ja active Active
-
2018
- 2018-05-03 MX MX2022011972A patent/MX2022011972A/es unknown
-
2021
- 2021-02-24 US US17/183,904 patent/US20210301027A1/en active Pending
- 2021-09-10 JP JP2021147378A patent/JP2021193120A/ja active Pending
-
2023
- 2023-02-15 JP JP2023021270A patent/JP7581399B2/ja active Active
- 2023-09-20 AU AU2023233110A patent/AU2023233110A1/en active Pending
-
2024
- 2024-10-29 JP JP2024189424A patent/JP2025020227A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018008900A2 (pt) | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas | |
| CL2019003657A1 (es) | Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275) | |
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| CO2017012974A2 (es) | Anticuerpos de unión a tau | |
| ECSP18005520A (es) | Anticuerpos de factor xi y métodos de uso | |
| MX2020001270A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39. | |
| CO2017012971A2 (es) | Anticuerpos de unión a tau | |
| BR112017017927A2 (pt) | receptores quiméricos de antígenos anti-dll3 e métodos de uso | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| BR112016014731A2 (pt) | Anticorpos anti-baff | |
| BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
| BR112016030908A2 (pt) | moléculas com especificidade para cd45 e cd79 | |
| BR112015020911A2 (pt) | anticorpo, uso de uma combinação e método de tratamento | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| MX2017010864A (es) | Anticuerpos contra tau y sus usos. | |
| MX377190B (es) | Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| BR112019023742A2 (pt) | anticorpos anti-trkb | |
| EA201891299A1 (ru) | Терапевтические антитела к cd9 | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |